Abstract:Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system.

Enhancing immunogenicity and antiviral protection of inactivated porcine reproductive and respiratory syndrome virus vaccine in piglets

GM-CSF fused with GP3 and GP5 of porcine reproductive and respiratory syndrome virus increased the immune responses and protective efficacy against virulent PRRSV challenge.

A porcine reproductive and respiratory syndrome virus (PRRSV)-specific IgM as a novel adjuvant for an inactivated PRRSV vaccine improves protection efficiency and enhances cell-mediated immunity against heterologous PRRSV challenge

Porcine ISG15 fused IFN-λ3 as a novel antiviral agent for treating porcine reproductive and respiratory syndrome virus infection in vivo

Construction and Immunogenicity of DNA Vaccines Encoding Fusion Protein of Porcine IFN- Λ 1 and GP5 Gene of Porcine Reproductive and Respiratory Syndrome Virus.

The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs.

Immune Responses of Pigs Immunized with a Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Porcine GM-CSF.

HSP70 Fused with GP3 and GP5 of Porcine Reproductive and Respiratory Syndrome Virus Enhanced the Immune Responses and Protective Efficacy Against Virulent PRRSV Challenge in Pigs.

Immunopotentiation of Four Natural Adjuvants Co-Administered with A Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus Glycoprotein 5 Subunit

Immune Responses in Pigs Induced by Recombinant DNA Vaccine Co-Expressing Swine IL-18 and Membrane Protein of Porcine Reproductive and Respiratory Syndrome Virus.

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo

An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs

An Innovative Approach to Induce Cross-Protective Immunity Against Porcine Reproductive and Respiratory Syndrome Virus in the Lungs of Pigs Through Adjuvanted Nanotechnology-Based Vaccination

Highly Efficient Expression of Interleukin-2 under the Control of Rabbit Beta-Globin Intron Ii Gene Enhances Protective Immune Responses of Porcine Reproductive and Respiratory Syndrome (prrs) Dna Vaccine in Pigs

Escherichia coli Heat-Labile Enterotoxin B Subunit Combined with Ginsenoside Rg1 as an Intranasal Adjuvant Triggers Type I Interferon Signaling Pathway and Enhances Adaptive Immune Responses to an Inactivated PRRSV Vaccine in ICR Mice

Enhanced Immune Responses of Mice Inoculated Recombinant Adenoviruses Expressing GP5 by Fusion with GP3 And/or GP4 of PRRS Virus

Cd40 Ligand Expressed in Adenovirus Can Improve the Immunogenicity of the Gp3 and Gp5 of Porcine Reproductive and Respiratory Syndrome Virus in Swine

Positive effects of porcine IL-2 and IL-4 on virus-specific immune responses induced by the porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 DNA vaccine in swine

Immunization with a recombinant fusion of porcine reproductive and respiratory syndrome virus modified GP5 and ferritin elicits enhanced protective immunity in pigs

Safety and Immunogenicity of the Recombinant Adenovirus Expressing the GP5 and M Protein of PRRSV in Piglets

Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines <i>in vivo</i>